Investigation of blood leptin and adropin levels in patients with multiple sclerosis
A CONSORT-clinical study

Ufuk Cinkir, MD\textsuperscript{a,\dagger}, Levent Sinan Bir, MD\textsuperscript{b}, Senay Topsakal, MD\textsuperscript{b}, Esin Avci Cicek, MD\textsuperscript{b}, Selma Tekin, MD\textsuperscript{b}

Abstract

Background: The effects of adipokines have been investigated in multiple sclerosis (MS) in the literature. Results are uncertain, and subgroups like adropin have not been previously studied. We primarily aimed to determine leptin and adropin levels in MS and their potential use as a biomarker.

Methods: This study was an experimental research. While 44 MS patients diagnosed according to McDonald criteria were included in the patient group, 40 people without MS diagnosis and risk factors took part in the control group. Demographic data, height, weight, body mass index, blood glucose, thyroid-stimulating hormone, alanine transaminase, aspartate transaminase, creatinine, low-density lipoprotein, leptin, adropin levels, presence of hypertension, diabetes mellitus, coronary artery disease were recorded. Expanded disability status scale and disease duration were also evaluated in the patient group. Our data were presented as mean ± standard deviations.

Results: The mean blood leptin value of the patient group (6.12 ± 5.34 ng/mL) was significantly lower than the value of the control group (13.02 ± 8.25 ng/mL) (\(P < .001\)). The patient group had a mean adropin level of 504.12 ± 311.17 ng/mL, which was significantly lower than that of the control group (747.0 ± 309.42 ng/mL) (\(P < .001\)). Statistically insignificant differences were found between their body mass index, glucose, alanine transaminase, aspartate transaminase, thyroid-stimulating hormone, low-density lipoprotein levels (\(P > .001\)).

Conclusion: This is the first study that has evaluated adropin levels in patients with MS. The relationship between MS and leptin levels is still unclear. Therefore, our study might be helpful to elucidate MS pathogenesis and provide supportive criteria for diagnosis.

Abbreviations: Akt = protein kinase B, CNS = central nervous system, EDSS = expanded disability status scale, L = liter, mL = milliliter, MS = multiple sclerosis, mTOR = mammalian target of rapamycin, n = number; ng = nanogram, pg = picogram, PI3K = phosphatidylinositol 3-kinase, RRMS = relapsing-remitting MS, SPMS = secondary progressive MS.

Keywords: adipokine, biomarker, inflammation, mammalian target of rapamycin, neurodegeneration

1. Introduction

MS is a chronic disease with neurodegeneration and inflammation that can present various signs and symptoms. It generally affects younger adults and is characterized by inflammation, demyelination, and axonal degeneration of the central nervous system (CNS).

MS may cause severe progressive disability. MS is more common in Caucasians, women, temperate, and high-income populations. In addition, it is thought to affect approximately 2 million people worldwide. A variety of lesions are observed in both white and grey matter of MS patients, which may cause several symptoms. The most common are loss of sensation, numbness, loss of motor strength and vision, dizziness, imbalance, diplopia, and bladder problems. Cognitive dysfunction and spasticity are considered as an indication of disease progression. That is, a wide variety of signs and symptoms may be seen due to the lesions.

Adipokines are among the hormones whose effects have been investigated in MS for several years. Leptin is an adipokine secreted from white adipose tissue and virtually affects the neuroendocrine system and immunomodulation. Some previous studies focused on the relationship between leptin levels and MS, yet those earlier studies are still inconsistent. Xie et al. found that higher serum leptin levels were found in MS patients compared with the control group. However, in 2018, Kvistad et al. demonstrated leptin and adiponectin were not useful as biomarkers of MS activity.

Adropin is a peptide hormone produced in the liver and brain involved in energy homeostasis, glucose and fatty acid metabolism, found at high concentrations in the brain and
involved in developing the cerebellum. We decided to investigate the level of adropin in MS, a neurodegenerative disease, due to its potential neuroprotective effects in the central nervous system. There is no study on adropin levels in MS so far.

We aim to determine leptin and adropin levels in MS patients, any potential relationship between leptin and adropin levels with the disease. Unlike previous studies, in this present original study, we studied whether there is any possible relationship between adropin levels and MS for the first time. To the best of our knowledge, this study may be a pioneer in the field.

2. Methods

2.1. Ethical review

The committee approved the ethical issues of the present study of Pamukkale University non-invasive clinical research ethics.

2.2. Participants

Definite MS patients, diagnosed according to McDonald MS criteria, were included in the patient group who had been evaluated in the department of neurology in the medical faculty (n = 44) of Pamukkale University, Denizli, Turkey. All patients were in remission but not in an attack period. The time elapsed since the last attack was unknown. Without MS diagnosis and risk factors (MS family history, coexisting certain autoimmune diseases, and infections such as systemic lupus erythematosus, Sjogren syndrome, Epstein-Barr virus infection, Lyme disease) were included in the control group. During the participants’ selection, all members were informed to participate in the study, and informed consent was obtained from each participant.

In each group, demographic data, height, weight, body mass index, blood glucose level, thyroid-stimulating hormone, alanine transaminase, aspartate transaminase, creatinine, low-density lipoprotein, leptin, adropin levels were measured, and present hypertension and diabetes mellitus, coronary artery disease was also recorded. Expanded disability status scale (EDSS) and disease duration were also determined in the patient group.

2.3. Blood collection

After obtaining informed consents, 5 mL of blood taken from the median cubital vein was transferred into yellow capped serum tubes containing separating gel. After blood was centrifuged (1500 × g for 10 minutes at +40°C), serum was separated and stored in Eppendorf tubes at −80°C prior to analyses.

2.4. Quantification of leptin and adropin

Adropin and leptin levels were determined by Y.L. Biont (Shangai Y.L. Biotech Co. Ltd, China) kits using enzyme-linked immunosorbent assay from the sera brought to room temperature on the day of analyses. Absorbance readings were carried out at a wavelength of 450 nm with a BioTek brand Enzyme-linked immunosorbent assay reader, and concentrations were calculated using the Gen 5 program. Within-run coefficient of variation levels for adropin and leptin were <8%, and inter-trial coefficient of variation <10%. Adropin reading range was between 5 and 1000 ng/L, while the kit’s sensitivity was 2.49 ng/L. The reading range of leptin was between 20 and 8000 pg/L, while the kit’s sensitivity was 10.83 pg/L.

2.5. Study design

Our study was experimental and cross-sectional clinical research.

2.6. Statistical analysis

Data were analyzed by the IBM SPSS 25 program (Armonk, New York, USA). As a result of the power analysis, it was calculated that if there were 29 people in the patient and control group, its validity would be achieved with a power of 80% with 95% confidence, and an independent sample t test was applied where parametric test assumptions were met. The Mann–Whitney U test was used for variables where parametric test assumptions were not provided. P ≤.01 was considered significant. Our data were presented as mean ± standard deviations.

3. Results

The mean age distribution of both groups was 39.71 ± 11.10. Of the all participants, there were 4 (4.8%) hypertensive and 80 (95.2%) non-hypertensive; 9 (10.7%) diabetic and 75 (89.3%) non-diabetic; 2 (2.4%) with coronary artery disease and 82 (97.6%) without coronary artery disease; 16 (19%) with hyperlipidemia and 68 (81%) participants without hyperlipidemia (Table 1).

Of the patient group in our study, 34 (77.3%) were women, 10 (22.7%) men, and the female/male ratio was 3.4, which was compatible with the literature (Supplemental Digital Content 1, http://links.lww.com/MD2/A419).

The mean EDSS of the patient group was 2.97 ± 2.17, and the mean disease duration was 9.58 ± 7.20; the mean number of attacks was 7.7 ± 8.4. There were 1 clinically isolated syndrome (2.3%), 37 relapsing-remitting MS (RRMS) (84.1%), 6 secondary progressive MS (SPMS) (13.6%) cases (Table 2).

The mean blood leptin value of the patient group was 6.12 ± 5.34 ng/mL. In comparison, it was 13.02 ± 8.25 ng/mL for the control group, and the difference was statistically significant (P < .001) (Table 3, Supplemental Digital Content 2, http://links.lww.com/MD2/A420). The mean adropin levels of the patient and the control groups were 504.12 ± 311.17 and 747.0 ± 309.42 ng/mL, respectively. And, the difference was statistically

| Table 1  | The demographic and physical data of all the participants. |
|----------|----------------------------------------------------------|
| Variable | Mean ± standard deviation | Median (minimum-maximum) |
| Age, yr  | 39.71 ± 11.10 | 40 (18–75) |
| Length, cm | 165.26 ± 9.06 | 164 (150–191) |
| Weight, kg | 71.15 ± 13.83 | 70 (40–110) |
| Body mass index | 26.04 ± 4.76 | 25.39 (15.6–38.2) |
| Gender | Women | 61 (72.6%) |
|          | Men | 23 (27.4%) |
| Hypertension | Yes | 4 (4.8%) |
|          | No | 80 (95.2%) |
| Diabetes mellitus | Yes | 9 (10.7%) |
|          | No | 75 (89.3%) |
| Coronary artery disease | Yes | 2 (2.4%) |
|          | No | 82 (97.6%) |
| High LDL level | Yes | 16 (19%) |
|          | No | 68 (81%) |

LDL = low density lipoprotein.
significant (P < .001) (Table 3, Supplemental Digital Content 3, http://links.lww.com/MD2/A421). Leptin and adropin values did not show any statistically significant difference between RRMS and SPMS groups (P < .001). The relationship between EDSS and leptin and adropin in the RRMS and SPMS groups was statistically insignificant (P > .001).

4. Discussion

This study is the first to evaluate adropin levels in MS patients to the best of our knowledge. We investigated whether adropin and leptin had a potential role in MS and whether they could be used as biomarkers by looking at blood adropin and leptin levels in patients with MS and healthy control groups.

MS is a chronic inflammatory and degenerative CNS disease that mainly affects young people. It is more common in White, women, temperate climates, and high-income societies. It is one of the leading causes of disability in young and middle-aged people in developed countries. Among the prevalence studies, it was reported that the MS prevalence was 101.4/100,000 in the study in the Maltepe district of Istanbul and 33.9/100,000 in the study in Edirne.

The mean age in Turkey has been reported as 41.8 ± 12.0 years, and in a study conducted in the Thrace region, it was found as 40.7 ± 10.6 years. Similarly, the patients’ mean age in our study was 40.75 ± 10.76 years. MS is more common among women. Worldwide, women with MS are about twice as high as men.

Table 2

| Variable         | Mean ± standard deviation | Median (minimum–maximum) |
|------------------|---------------------------|--------------------------|
| EDSS             | 2.97 ± 2.17               | 2 (0–9)                  |
| Disease duration, y | 9.58 ± 7.20              | 7 (4–42)                 |
| Number of attacks | 7.7 ± 8.47                | 4.5 (1–30)               |
| n (%)            |                           |                          |
| MS form          |                           |                          |
| RRMS             | 37 (84.1%)                |                          |
| SPMS             | 6 (13.6%)                 |                          |
| CIS              | 1 (2.3%)                  |                          |

CIS = clinical isolated syndrome, EDSS = expanded disability status scale, MS = multiple sclerosis, RRMS = relapsing-remitting multiple sclerosis, SPMS = secondary progressive multiple sclerosis.

Table 3

| Variable | Patient group (n = 44) | Control group (n = 40) | P  |
|----------|------------------------|------------------------|----|
| Age      | 40.75 ± 10.76          | 38.58 ± 11.49          | .375|
| Height   | 164.14 ± 9.0           | 166.5 ± 9.06           | .235|
| Weight   | 68.95 ± 14.62          | 73.58 ± 12.65          | .124|
| BMI      | 25.63 ± 5.2            | 26.51 ± 4.20           | .404|
| Glucose  | 98.30 ± 20.90          | 102.33 ± 26.04         | .439|
| TSH      | 2.05 ± 1.75            | 1.76 ± 0.81            | .330|
| ALT      | 24.25 ± 22.66          | 16.88 ± 10.77          | .036|
| AST      | 20.61 ± 12.94          | 15.68 ± 4.84           | .022|
| Creatinin| 0.69 ± 0.17            | 0.78 ± 0.15            | .012|
| LDL      | 110.87 ± 31.51 (n = 38)| 119.68 ± 38.33 (19)    | .303|
| Leptin   | 6.12 ± 5.34            | 13.02 ± 8.25           | .0001|
| Adropin  | 504.12 ± 311.17        | 747.0 ± 309.42         | .0001|

ALT = alanine transaminase, AST = aspartate transaminase, BMI = body mass index, LDL = low density lipoprotein, TSH = thyroid-stimulating hormone.
and survival. This path also triggers the mTOR pathway. Phosphorylated-Akt ensures cell cycle, proliferation, differentiation, plasticity, in population. Secondly, our population potential treatments for neurodegenerative diseases like MS metabolism, the effects of increased adropin levels on the biomarker in MS patients. Besides, considering its role in energy between the 2 groups, adropin levels might be used as a between MS and adropin in the literature. Our results indicated cation of adropin as a molecular and transcriptional signature controlling CD4+ effector T cell responses. J Immunol 2012;189:2941–53. Again, like leptin, low adropin levels may impair angiogenesis and regeneration and disrupt synaptic plasticity. In our study, the patient group had a level of adropin significantly lower than the control group (P < .001), which may lead us to the fact that adropin deficiency may promote inflammation and neurodegeneration in the CNS and/or contribute to the formation of MS. There has not been any study investigating the relationship between MS and adropin in the literature. Our results indicated that based on the significant difference in the adropin levels between the 2 groups, adropin levels might be used as a biomarker in MS patients. Besides, considering its role in energy metabolism, the effects of increased adropin levels on the potential treatments for neurodegenerative diseases like MS should be determined in future studies.

On the other hand, we had some limitations in our study. Firstly, there was no primary progressive MS in our patient population. Secondly, our population’s count was quite limited (84 participants). The last limitation was that we did not evaluate patients and biochemical parameters according to disease subgroups. Larger patient groups, including primary progressive MS and divided subgroups, should be studied further.

In conclusion, the relationship between MS and leptin level is not clear in the literature. This study is the first on the potential relationship between MS and blood adropin levels to the best of our knowledge. The role of blood leptin and adropin levels should be taken into consideration in patients with MS. Their levels may be used as a predictive value for MS in the future and can provide valuable information about the course of this disease.

Author contributions

Conceptualization: Ufuk Cinkir.
Data curation: Ufuk Cinkir.
Formal analysis: Ufuk Cinkir, Senay Topsakal, Esin Avci Cicek.
Funding acquisition: Ufuk Cinkir, Senay Topsakal.
Investigation: Ufuk Cinkir, Levent Sinan Bir, Senay Topsakal, Esin Avci Cicek.
Methodology: Ufuk Cinkir, Levent Sinan Bir, Senay Topsakal, Esin Avci Cicek.
Project administration: Ufuk Cinkir.
Resources: Ufuk Cinkir, Esin Avci Cicek.
Supervision: Ufuk Cinkir, Selma Tekin.
Validation: Ufuk Cinkir.
Visualization: Ufuk Cinkir.

References

[1] Koch-Henriksen N, Sorensen PS. The changing demographic pattern of multiple sclerosis epidemiology. Lancet Neurol 2010;9:520–32.
[2] GBD 2016 Multiple Sclerosis CollaboratorsGlobal, regional, and national burden of multiple sclerosis 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 2019;18:269–85.
[3] Milo R, Kahana E. Multiple sclerosis: geoepidemiology, genetics and the environment. Autoimmun Rev 2010;9:A387–94.
[4] Fox RJ, Rae-Grant AD, Béthoux F. Multiple Sclerosis and Related Disorders: Clinical Guide to Diagnosis, Medical Management, and Rehabilitation. 2018;Springer Publishing Company, NY, USA.
[5] Procaccini C, De Rosa V, Galgani M, et al. Leptin-induced mTOR activation defines a specific molecular and transcriptional signature controlling CD4+ effector T cell responses. J Immunol 2012;189:2941–53.
[6] Lubini FD, Reingold SC, Cohen JA, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology 2014;83:278–86.
[7] Xie XF, Huang XH, Shen AZ, Li J, Sun YH. Association between circulating leptin levels and multiple sclerosis: a systematic review and meta-analysis. Postgrad Med J 2018;94:278–83.
[8] Kwistad SS, Myhr KM, Holmøy T, et al. Serum levels of leptin and adiponectin are not associated with disease activity or treatment response in multiple sclerosis. J Neuroimmunol 2018;323:73–7.
[9] Kumar KG, Trevaskis JL, Lam DD, et al. Identification of adropin as a secreted factor linking dietary macronutrient intake with energy homeostasis and lipid metabolism. Cell Metab 2008;8:468–81.
[10] Lovren F, Pan Y, Quan A, et al. Adropin is a novel regulator of endothelial function. Circulation 2010;122(11 suppl):S185–92.
[11] Gao S, McMullan RP, Jacobs J, et al. Regulation of substrate oxidation preferences in muscle by the peptide hormone adropin. Diabetes 2014;63:3242–52.
[12] Gozal D, Kheirandish-Gozal L, Bhattacharjee R, Molero-Ramirez H, Tan H, Bandla HPR. Circulating adropin concentrations in pediatric obstructive sleep apnea: potential relevance to endothelial function. J Pediatr 2013;163:1122–6.
[13] Cui XY, Hu QD, Tekaya M, et al. NB-3/Notch1 pathway via Delta1 promotes neural progenitor cell differentiation into oligodendrocytes. J Biol Chem 2004;279:25858–65.
[14] Turk Borus U, Alp R, Sur H, Gul L. Prevalence of multiple sclerosis door-to-door survey in Maltepe, Istanbul, Turkey. Neuroepidemiology 2006;27:17–21.
[15] Çelik V, Birgili O, Kiyat A, et al. Prevalence of multiple sclerosis in the metropolitan area of Edirne City, Turkey. Balkan Med J 2011;28:193–6.
[16] Celebi C, Solmaz V, Inalçak Y, Çelik Y. The evaluation of clinical, demographic, radiological characteristics and treatment response of multiple sclerosis patients in Thrace region. Kafkas J Med Sci 2017;7:231–5.
[17] Marris RA, Yu BN, Leung S, et al. Raising prevalence of vascular comorbidities in multiple sclerosis: validation of administrative definitions for diabetes, hypertension, and hyperlipidemia. Mult Scler 2012;18:1310–9.
[18] Dardeno TA, Chou SH, Moon HS, Chamberland JP, Fiorenza CG, Manzoros CS. Leptin in human physiology and therapeutics. Front Neuroendocrinol 2010;31:377–93.
[19] Dalamaga M, Chou SH, Shields K, Papageorgiou P, Polyzos SA, Manzoros CS. Leptin at the intersection of neuroendocrinology and metabolism: current evidence and therapeutic perspectives. Cell Metab 2013;18:29–42.
[20] Ahuma RS, Osei SY. Leptin signaling. Physiol Behav 2004;81:223–41.
[21] Kelesidis T, Kelesidis I, Chou S, Manzoros CS. Narrative review: the role of leptin in human physiology: emerging clinical applications. Ann Intern Med 2010;152:93–100.
[22] Evangelopoulos ME, Koutsis G, Markianos M. Serum leptin levels in treatment-naïve patients with clinically isolated syndrome or relapsing-remitting multiple sclerosis. Autoimmune Dis 2014;1:–6. ID 486282.
[23] Batocchi AP, Rotondi M, Caggula M, et al. Leptin as a marker of multiple sclerosis activity in patients treated with interferon-beta. J Neuroimmunol 2003;139:150–4.
10.

Annovazzi L, Mellai M, Caldera V, Valente G, Tessitore L, Schiffer D. mTOR, S6 and AKT expression in relation to proliferation and apoptosis/autophagy in glioma. Anticancer Res 2009;29:3087–94.

11.

Chen H, Qu Y, Tang B, Xiong T, Mu D. Role of mammalian target of rapamycin in hypoxic or ischemic brain injury: potential neuroprotection and limitations. Rev Neurosci 2012;23:279–87.

12.

Wong CM, Wang Y, Lee JT, et al. Adropin is a brain membrane-bound protein regulating physical activity via the NB-3/Notch signaling pathway in mice. J Biol Chem 2014;289:25976–86.

13.

Gao S, McMillan RP, Zhu Q, Lopaschuk GD, Huver MW, Butler AA. Therapeutic effects of adropin on glucose tolerance and substrate utilization in diet-induced obese mice with insulin resistance. Mol Metab 2015;4:310–24.

14.

Sakurai K, Toyoshima M, Ueda H, Matsubara K. Contribution of the neural cell recognition molecule NB-3 to synapse formation between parallel fibers and Purkinje cells in mouse. Dev Neurobiol 2009;69:811–24.

15.

Yang C, DeMars KM, Hawkins KE, Candelario-Jalil E. Adropin reduces paracellular permeability of rat brain endothelial cells exposed to ischemia-like conditions. Peptides 2016;81:29–37.

16.

Zhao Y, Li J, Tang Q, et al. Regulation of extracellular signal-regulated kinase 1/2 influences hippocampal neuronal survival in a rat model of diabetic cerebral ischemia. Neural Regen Res 2014;9:749–56.

17.

Mu D, Jiang X, Sheldon RA, et al. Regulation of hypoxia-inducible factor 1alpha and induction of vascular endothelial growth factor in a rat neonatal stroke model. Neurobiol Dis 2003;14:524–34.

18.

Colin E, Régulier E, Perrin V, et al. Akt is altered in an animal model of Huntington’s disease and in patients. Eur J Neurosci 2005;21:1478–88.

19.

Griffin RJ, Moloney A, Kelliher M, et al. Activation of Akt/PKB, increased phosphorylation of Akt substrates and loss and altered distribution of Akt and PTEN are features of Alzheimer’s disease pathology. J Neurochem 2005;93:105–17.

20.

Saavedra A, García-Martínez JM, Xifré X, et al. P.H. domain leucine-rich repeat protein phosphatase 1 contributes to maintain the activation of the PI3K/Akt pro-survival pathway in Huntington’s disease striatum. Cell Death Differ 2010;17:324–35.

21.

Burke RE. Inhibition of mitogen-activated protein kinase and stimulation of Akt kinase signaling pathways: two approaches with therapeutic potential in the treatment of neurodegenerative disease. Pharmacol Ther 2007;114:261–77.

22.

Blanco-Aparicio C, Renner O, Leal JFM, et al. PTEN, more than the AKT pathway. Carcinogenesis 2007;28:1379–86.

23.

Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell 2007;129:261–77.

24.

Li W, Yang Y, Hu Z, Ling S, Fang M. Neuroprotective effects of DAHP and Triptolide in focal cerebral ischemia via apoptosis inhibition and PI3K/Akt/mTOR pathway activation. Front Neuroanat 2015;9:1–2. Article 48.

25.

Cota D, Proulx K, Smith KA, et al. Hypothalamic mTOR signaling regulates food intake. Science 2006;312:927–30.